Primary central nervous system lymphoma (PCNSL) is a rare disorder that, in 95% of cases, represents diffuse large B-cell lymphoma. As such, making an accurate diagnosis is important. At present, stereotactic-guided biopsy is a recognized method of choice for tissue analysis. However, the diagnostic work-up for high-risk patients is determined by their performance status. Here, we report a case of PCNSL in a high-risk patient, for whom diagnosis was established by cerebrospinal fluid cytology and flow cytometry, which significantly shortened a diagnostic work-up period and allowed for the immediate treatment of the patient.
Introduction
Primary central nervous system lymphoma (PCNSL) comprises all cases of lymphomas that exclusively involve the brain, spinal cord, eyes, meninges, and cranial nerves in the absence of systemic lymphoproliferative process upon diagnosis. Some registry reports declare that PCNSL represents 4% of all intracranial tumors and 4%-6% of all extranodal lymphomas (NHL) 1 . However, recent studies suggest that the incidence of PCNSLs, especially among the elderly is increasing 2 . Although the vast majority of all PCNSL cases correspond to diffuse large B-cell lymphoma (DLBCL) 3 , the World Health Organization classification considered PCNSL as a discrete entity 4 . Owing to the absence of typical clinical presentation, molecular biology and immunohistochemistry are important in making an accurate PCNSL diagnosis 5 . At present, stereotactic-guided biopsy is a recognized method of choice for tissue analysis. In this article, we report a case of primary DLBCL of the central nervous system (CNS) established by cerebrospinal fluid (CSF) flow cytometry, which extremely shortened the diagnostic work-up period.
Case report
A 52-year old patient complaining double vision and ataxia was presented to the N.N. Blokhin Russian Cancer Research Center. His state of health, assessed by the Eastern Cooperative Oncology Group (ECOG) Performance Status, corresponded to ECOG-3. The patient initially underwent PET-scanning, performed by the community-based care (Figure 1 ), which revealed a 2.4 cm × 1.4 cm mass in the left cerebellum hemisphere with maximal standardized uptake value (SUV) 40.67 and spinal cord FDG uptake at the Th11-S2 level with maximal SUV 13.05. Subsequent neurological examination revealed left blepharoptosis (MRD-2), facial hyposensitivity at the level of the left nervus mandibularis innervation, both side missed finger-to-nose test, and instability in the Romberg's stance. Blood count showed leucocytosis (19.39 × 10 9 /L). Serum test revealed an elevated LDH (610 units/L) level. Contrast-enhanced MRI in the T2, T2-flair, and DWI regimen also revealed two lesions in the left cerebellum hemisphere (Figure 2) : the first was 2.8 cm × 1.6 cm in size; the second had a diameter of 1.0 cm and was located laterally to the first. Lumbar puncture was performed, and liquor analysis revealed cellularity of 1820 cells/mL, with 73% of blast cells and protein level above 1 g/L. Cytology examination of CSF demonstrated large centroblastic-type cells with high mitosis frequency, which were suspicious for lymphoma (Figure 3) . Immunophenotyping of CSF (Figure 4 ) revealed that 55% of cells corresponded to k-clonal CD5, CD10 -negative, CD19, CD20, CD45 -positive B-cell lymphocytes that, together with conventional cytology, indicated DLBCL. Bone marrow examination revealed no evidence of lymphoma dissemination. In the absence of testis lesions by ultrasound, peripheral lymphadenopathy and no other organ involvement, the diagnosis for PCNSL was made.
The patient was recommended for intrathecal therapy, 
Discussion
PCNSL is a rare disorder that strongly correlates with immunodeficiency. Although this link has already been reported, no exact mechanism has yet been identified 6 . Moreover, the incidence of PCNSL in immunocompetent patients is increasing 7 .
Radiotherapy has been the only effective treatment method for patients with PCNSL for a long time. However, despite a Stereotactic biopsy is the method of choice in diagnosing PCNSL and is widely recommended. However, we suggest that this recommendation should be applied only for lowrisk patients. The need for CSF analysis for patients requiring urgent treatment cannot be underestimated. According to some studies, CSF cytomorphology can detect lymphoma cells in 18% of newly diagnosed PCNSL cases 11 . Another report has proven that flow cytometric immunophenotyping is twice more sensitive than classic cytomorphology for diagnosing CNS localizations of hematologic malignancies (77% against 32%) 12 , thus demonstrating that a combination of these two methods is a strong tool in PCNSL diagnosis. Additionally, this strategy is associated with reduced methodrelated complications. However, further studies including case reports are needed, because they may represent opportunities to obtain additional clinical information to support the feasibility of this approach.
